Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Alternative Payment Models
- Biopharmaceutical Innovation
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Utilization Management & Step Therapy
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 11 Results
NPC Provides Comments to CMS on the Notice of Benefit and Payment Parameters (NBPP) for Calendar Year 2026
NPC submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the proposed provisions to alter the affordability, quality, accessibility of Marketplace health insurance,…
NPC Submits Comments Regarding the Medicare Hospital Outpatient Prospective Payment System
NPC submitted comments to CMS regarding the Medicare Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for Calendar Year 2025.
NPC Submits Comments to CMS on Proposed Rule on CY 2025 Payment Policies and More
In response to CMS' request for comments, NPC shared its input on the proposed rule for payment policies under the Medicare Physician Fee Schedule for calendar year 2025.
NPC responds to CMS's Information Collection Request on the Negotiation Data Elements and Drug Price Negotiation Process for the Initial Price Applicability Year 2027
NPC offered the agency insights on the data collection requirements it has proposed to inform the second round of the the price-setting efforts in the Medicare Drug Price Negotiation Program.
NPC Submits Comments to CMS on Draft Guidance for the Medicare Drug Price Negotiation Program for 2027
In this comment letter, NPC weighs in on CMS' s draft guidance regarding the second cycle of the Medicare Drug Price Negotiation Program.
NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
NPC submitted comments to the National Institute of Standards and Technology in response to the Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise…
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025
In this comment letter, NPC offers input on HHS' Notice of Benefit and Payment Parameters for 2025, annual rulemaking that governs programs and health plans offered under the Affordable Care Act.
NPC Submits Comments to CMS on Proposed Changes to Medicare Programs
In this comment letter, NPC weighs in on CMS' proposed technical and policy changes to Medicare Advantage and other Medicare programs.
NPC Submits Comments to CMS on Medicaid Drug Rebate Program
In this comment letter, NPC weighs in on CMS' proposed rule changes to the Medicaid Drug Rebate Program (MDRP).
NPC Comments on the Medicare Program's Hospital Inpatient Prospective Payment Systems
NPC's comments to CMS focus on recent proposals related to the transition to National Drug Codes for New Technology Add-on Payments and recommendations regarding payment mechanisms to improve access…
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.